2017 American Transplant Congress
Immediate vs Delayed Initiation of CMV Prophylaxis…Safe and Cost Beneficial?
University of Utah Health Care, Salt Lake City, UT
Background: Recommendations differ on when to initiate valganciclovir (VGCV) for CMV prophylaxis (ppx) after tx. Current labeling states within 10 days of tx. We evaluated…2016 American Transplant Congress
Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.
Transplant & Oncology Infectious Disease, The Johns Hopkins University, Baltimore.
Background: Treatment of GCV-resistant(GCV-R)or refractory CMV infections in hematopoietic stem cell transplant (HSCT)and solid organ transplant (SOT)recipients remains controversial.Foscarnet (FOS)and cidofovir(CDV),nucleotide analogues with activity against…2016 American Transplant Congress
Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?
Transplant Institute, Tulane University School of Medicine, New Orleans, LA.
Purpose: Infection is one of the most common and costly complications of solid organ transplantation. Alemtuzemab (AL) is a powerful antibody that significantly reduced rejection…2016 American Transplant Congress
Cytomegalovirus Infection After Cardiac Transplantation.
University of British Columbia, Vancouver, Canada.
BackgroundOrthotopic heart transplantation (OHT) continues to be the gold standard for the management of patients with end-stage heart failure. However, complications following OHT may result…2016 American Transplant Congress
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel IS agent that acts through costimulatory blockade of T-cells and obviates the need for CNI. Despite benefits in improving renal…2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…2016 American Transplant Congress
Impact of Morbid Obesity on Breakthrough CMV Infection in Kidney Transplant Recipients.
Medical University of South Carolina, Charleston, SC.
Purpose: The aim of this study was to assess the impact of obesity on risk for cytomegalovirus (CMV) infection after kidney transplantation as well as…2016 American Transplant Congress
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
Human cytomegalovirus (CMV) infection is one of the primary opportunistic pathogens and is a leading cause of morbidity and mortality in kidney transplant recipients. Assessing…2016 American Transplant Congress
Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.
Multi-Organ Transplant, University Health Network, Toronto, Canada.
BackgroundSimple standardized measures of global immunity may help predict the risk of infections post-transplant. The Quantiferon-Monitor (QFM) test is a novel interferon-γ (IFN-γ) release assay…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 33
- Next Page »